NCT07213973View on ClinicalTrials.gov

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

December 14, 2025

Primary Completion Date

March 25, 2028

Study Completion Date

March 25, 2028

Conditions

Hidradenitis Suppurativa (HS)

Interventions

DRUG

Povorcitinib

Oral; Tablet

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY

NCT07213973 - Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter